COMMUNIQUÉS West-GlobeNewswire

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
02/10/2025
ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct. 02, 2025 (GLOBE [...]
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
02/10/2025
AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutation AAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue recruiting in our STELLA [...]
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
02/10/2025
SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary [...]
Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder
02/10/2025
DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before the end of 2025 Trial builds on positive Phase 1 study that showed [...]
George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil
02/10/2025
Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, [...]
Bimergen Energy Secures $50 Million for Battery Energy Storage Project Development
02/10/2025
Newport Beach, CA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation [ OTCQB: BESS ], (“the Company” or “Bimergen”), a developer of utility-scale battery energy storage solutions and an independent power [...]
Immuron Letter to Shareholders – Projects Update
02/10/2025
Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products Travelan ® Clinical Study: Topline results from the Travelan ® clinical study [...]
Pennant Completes Purchase of Tennessee, Georgia and Alabama Operations from UnitedHealth Group and Amedisys
02/10/2025
EAGLE, Idaho, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today [...]
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
02/10/2025
STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
02/10/2025
Utrecht, The Netherlands, October 2, 2025 – AM-Pharma B.V. today announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention of [...]
Precision Neuroscience Reports First High-Bandwidth Brain–Computer Interface Achieved Without Open Surgery
02/10/2025
Study in Nature Biomedical Engineering details Precision’s surface-based system and shows results from the first five patients NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), [...]
Igyxos Biotherapeutics Awarded EUR 5.7 Million from the French Government to Accelerate Development of its First-in-class Monoclonal Antibody for the Treatment of Infertility
02/10/2025
TOURS, France, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced that it has secured a [...]
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
02/10/2025
Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 [...]
Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés
02/10/2025
Communiqué de presse Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés Les analyses additionnelles préplanifiées de l’ [...]
e-therapeutics relance son activité sous le nom de Tangram Therapeutics et présente LLibra OS
02/10/2025
Ce renouveau marque une étape décisive dans la croissance de la Société, qui prévoit de soumettre sa première demande d’essai clinique (ou CTA, de l’anglais « Clinical Trial Application ») au quatrième trimestre 2025. [...]
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
02/10/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of [...]
New Imprivata Report Finds that Australian Hospitals Save More Than $1.2 Million AUD Annually with Shared-Use Mobile Devices, but Strategic Gaps Still Pose Security and Operational Risk
02/10/2025
The 2025 Imprivata State of Shared Mobile Devices in Healthcare Report identifies the benefits as well as the challenges Australian healthcare organisations face when implementing shared-use mobile devices for clinical [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2025
SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for [...]
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
01/10/2025
Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB) at a price of $14. [...]

Pages